Source: Blood. Conference titles: Annual meeting and Exposition of American Society of Hematology (ASH). Unidades: ICB, FMRP
Subjects: QUIMIOTERAPIA, NEOPLASIAS, DOENÇAS HEMATOLÓGICAS
ABNT
FENERICH, Bruna Alves et al. The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: http://www.bloodjournal.org/content/130/Suppl_1/1253. Acesso em: 19 maio 2024. , 2017APA
Fenerich, B. A., Machado Neto, J. A., Alves, A. P. N. R., Campos, P. de M., Fernandes, J. C., Coelho-Silva, J. L., et al. (2017). The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Recuperado de http://www.bloodjournal.org/content/130/Suppl_1/1253NLM
Fenerich BA, Machado Neto JA, Alves APNR, Campos P de M, Fernandes JC, Coelho-Silva JL, Ribeiro RS, Silva FB da, Scheucher PS, Figueiredo-Pontes LL, Rego EM, Traina F. The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms [Internet]. Blood. 2017 ; 130[citado 2024 maio 19 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/1253Vancouver
Fenerich BA, Machado Neto JA, Alves APNR, Campos P de M, Fernandes JC, Coelho-Silva JL, Ribeiro RS, Silva FB da, Scheucher PS, Figueiredo-Pontes LL, Rego EM, Traina F. The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms [Internet]. Blood. 2017 ; 130[citado 2024 maio 19 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/1253